

Arab Journal of Nuclear Sciences and Applications

Web site: ajnsa.journals.ekb.eg



Dosimetric Evaluation of the Physical Parameters for Different Energies in Advanced **Radiotherapy Technique for Liver Cancer**

S. Hassn^{1*}, Khaled M. El-Shahat², M.F.Eissa³ and A.H. Alv³

⁽¹⁾Minia Oncology Center, Ministry of Health and Population, Minia, Egypt ⁽²⁾Clinical Oncology Department, Faculty of Medicine, Al-Azhar University, Egypt ⁽³⁾Physics Department, Faculty of Sciences, Beni-Suef University, Beni Suef, Egypt

ARTICLE INFO

Article history:

ABSTRACT

Received: 31st Jan. 2021 Accepted: 5th Aug. 2021.

Keywords:

6-MV. 10-MV.

Double Photon Energies; Intensity-Modulated Radiation Therapy (IMRT) photon energy.

This work aims to study dosimetrically compared 6MV, 10MV, and dual energies (DE) photon beam energies in patients with liver cancer. Evaluating the effect of using different energies on intensity-modulated radiation (IMRT) outcome were selected. Stepand-shoot IMRT treatment plans were designed for delivery on an Elekta linear accelerator with 160 leaves. Identical optimization constraints were applied for all energy plans. Parameters such as beam angle and number of beams were kept constant to achieve the same clinical objectives. Both qualitative and quantitative methods were used. Many physical indices for Planning Target Volume (PTV), the relevant Organs at Risk (OARs) as mean dose (Dmean), maximum dose (Dmax), 95% dose (D95), and also the number of monitor units (MU) were applied.

Twenty eight virtual IMRT treatment plans were involved in this study. the plans depended on Monaco's (IMRT) treatment plan outcome. For each case, three plans with the same beam geometry were created using 6 MV, 10 MV, and DE. For dual energy plans, all cases were optimized with identical planning objectives and normalized such that 98% of the target received 100% of the prescription dose.

The three techniques showed comparable PTV inhomogeneity and conformity for all patient's differences within the median values <0.6%10 MV and DE plans and a statistically important reduction in the total number of monitor units (MU) of 14.2% (p < 0.01) and 13.3% (p < 0.01) as compared to 6 MV, respectively. It could be concluded that each dual energy and 10 MV energy had similar PTV dosimetry characteristics.

1.INTRODUCTION:

Radiation therapy uses targeted radiation for the treatment of cancer. The radiation is often in form of x-ray beams. Conventional external beam radiation therapy is not usually used for secondary liver cancer; however, two specialized forms of radiotherapy may be used in some cases [1].

In the treatment of hepatocellular carcinoma (HCC), radiotherapy (RT) had a limited role because the whole liver is little tolerant to RT in addition to the risk of radiation-induced liver disease (RILD) [2]. Even though in many guidelines, using RT has been restricted, the new versions of the National Comprehensive Cancer Network (NCCN) guidelines as well as the National Cancer Center Korea recommended the use of RT as a local treatment modality [3].

It is therefore necessary to have high-quality beam data to avoid dosing errors and patient treatment [1]. Conventional external beam radiation therapy is not usually used for secondary liver cancer; however, two specialized forms of radiotherapy may be used in some cases [2].

In the therapy of hepatocellular carcinoma (HCC), radiotherapy (RT) had a restricted job in the light of the fact that the entire liver is of minimal tolerance to RT notwithstanding the danger of radiation-actuated liver illness (RILD) [2]. Despite the fact that, in numerous rules, utilizing of RT has been limited, the new forms of the National Cancer Center of Korea suggested utilizing of RT as a nearby therapy methodology [3]. There is an obvious association between the dosage of radiation and the possibility of tumor control in several tumors, but the

tumor dosage is frequently restricted by the radiation tolerance of the surrounding tissues. IMRT may permit saving more normal and healthy tissues as compared to different strategies through more exact adaptation to the selected target. Therefore, this gives the likelihood of both the reduction of late harmfulness and the expansion of the conveyed portion that can bring about progress in tumor control just as endurance [4]. Consequently, this gives the probability of both the decrease of late toxicity and the increase of the delivered dose that can result in improvement in tumor control as well as survival [5].

In HCC, the size of the tumor and its position in the liver determine the appropriate surgery in some patients while radiation therapy is appropriate for others. For example, radiation therapy is a possible treatment for early-stage primary lesions or oligometastatic disease due to its local control of liver diseases [6].

The IMRT has distinct features when compared to the earlier techniques for treatment such as 3DCRT. These features are the converse treatment planning process and the conformal beam which target a large number of therapeutic fields or subfields [7].

Therefore, the IMRT offers an incredible precision and a magnificently conformal portion appropriation through different bars, with a non-uniform force profile for every one of them. There are three sorts of IMRT conveyance frameworks, which permit the development of nonuniform power profiles the moderate multi-leaf collimator (MLC)- mounted straight quickening agents. These three kinds are: (1) step-and-shoot IMRT, where little MLC-produced fragments are utilized, and there is no conveyance for the radiation while the leaves move for the formation of the following section, (2) sliding window IMRT, where tweaked MLC speed in various static radiation fields is utilized, and there is no conveyance for the radiation as the leaves are moving, and (3) volumetric adjusted bend treatment (VMAT), that is a rotational type of IMRT where, all through the turn, moving MLC and changing portion conveyance rates happen [7].

Consequently, the IMRT offers incredible precision and a magnificently conformal dose distribution via multiple beams, with a non-uniform intensity profile for each of them. There are three types of IMRT delivery systems, which allow the formation of non-uniform intensity profiles, equipped with the conservative multileaf collimator (MLC)-mounted linear accelerators. These three types are as follows: (1) step-and-shoot IMRT, where small generated MLC segments are used, and there is no delivery for the radiation while the leaves move for the creation of the next segment, (2) sliding window IMRT, where modulated MLC velocity in multiple static radiation fields are used, and there is no delivery for the radiation as the leaves are moving, and (3) volumetric modulated arc radiation therapy (VMAT), that is a rotational form of IMRT where, throughout the rotation, moving MLC and dynamic dose delivery rates happen [8].

Hence, the principal objective of the examination is to decide the smallness of the objective portion dispersion for liver malignant growth plans utilizing 6MV, 10MV, and DE. Accordingly, evaluation of the conservativeness is conducted regarding tumble off for both higher iso-portion levels and lower isodose levels. This current examination's goal is the measurement of the impact of photon bar energy determination on liver portion dispersions and treatment plan quality.

2. MATERIALS AND METHODS

2.1. Status selection and simulation

The current retrospective treatment planning study included twenty-eight subjects. The subject was previously treated from liver diseases. Every patient was immobilized by the Body Pro-Lok[™] system (CIVCO, Orange City, IA) with his arms upwards, with application abdominal compression of through a compression plate to reduce the movement of breathing. A free-breathing helical CT scan was applied for all the patients for simulation by a 2mm slice thickness. The gross tumor volume (GTV) was segmented where the simulation CT scan study was used by a highly certified radiation oncologist.

Delineation of the planning target volume (PTV) was performed via adding a setup margin, usually 5mm in the anterior-posterior and lateral direction and 10mm in the superior-inferior direction. The dose prescription and fractionation differed across the patients' sample and ranged from 54 Gy (3 fractions) to 50 Gy (5 fractions).

2.2. Beam Energy Selection

Planning of the initial treatment was done using 6MV photon energy for all beams. After that, re-planning of the patients was carried out using 10MV photon energy for all beams. A simple approach based on the central axis depth to the Isocenter was utilized for the dual-energy (DE) photon plans, for a given beam it was used for determination of the used 6MV or 10MV energy. Along the beam's central axis to the Isocenter, the effective depth was detected for every patient. For a given patient, all beams' effective depths were

averaged and the beams possessing an effective depth below the average were set at the energy of 6MV, while the rest were set at 10MV energy. This approach was used to confirm an even split between 6MV and 10MV photon energies for the greater part of the patients. The use of 10MV for the greater part was owing to the basis for effective depth that mainly based on that the penetrative power of 10MV is greater than 6MV.

The total number of the patients was planned in the Monaco treatment planning system (TPS) version 5.11 2 IMRT beams with 6MV, 10MV, and DE. The orientations of the beam were selected for minimizing the beam overlap and OAR irradiation. For plan optimization and dose calculation, DMPO optimization was employed with a final dose calculation by the Monte Carlo, adaptive convolve algorithm calculation for high-quality dependable treatment planning result.

For each patient, there were no variations in the collimator, gantry, and couch angles within a patient when comparing 6MV, 10MV, and DE plans. All other settings of the plan were equivalent but differed among patients. All plans were optimized with similar planning objectives and normalized such that 98 % of the PTV received 100 % of the prescription.

2.3. Treatment planning techniques

In the present study, the inverse plan Dose Volume Optimizer (DVO version 5.11.02) of the Monaco planning system was used for IMRT technique planning. Within the IMRT technique, the delivery of the radiation dose was done for planning target volume (PTV). For PTV and the other critical organs (as bladder, rectum, lungs, and kidneys), proper dose-volume constraints for IMRT plan optimization were used. For PTV optimization, constraints were such that 100% PTV volume ought to be 99.2% and 98% minimal dose, while maximal dose ought to be less than 102.2% and 103% for zero % volume respectively. Radiation dose deliveries were planned in two phases. IMRT plans were generated for both 6MV photon beam using two delivery modes (SS) and (SW) with seven coplanar non-opposed beam arrangements of 0°,51°,103°,154°,206°,257°,308° gantry angles for all patients to ensure identical beam angle arrangements. The radiation dose of 50.4Gy and 30.6Gy with 1.8Gy/fraction were planned for the doses to the OARs were restricted by the RTOG guidelines for critical structure dose. Depending on the list of PTV and OAR plan constraints is shown in Tables 1 (Fig. 1), comparative analysis, Dose-volumetric analysis of each energy IMRT plan was performed by both qualitative and quantitative methods for the normal tissue doses.

Table (1):	The	diagnosing,	prescription	dose, patient
	volu	me and PTV	volume for th	e investigated
	cases	5		

patient number	Prescribed Dose (cGy)	PTV Volume (CC)	Patient Volume (cc)
1	4500	527.695	13964.435
2	4500	316.8	17691
3	5400	344.52	14348
4	4500	96.75	16277.8
5	4500	695.52	21697
6	4500	138.5	20131.6
7	5400	641.41	23534.8
8	4500	278	23524
9	5400	153.7	1734.23
10	5400	382.53	217252
11	4500	253.25	17392
12	4500	541.2	20517
13	4500	653.21	15621
14	4500	527.695	13964.435
15	4500	316.8	17691
16	5400	344.52	14348
17	4500	96.75	16277.8
18	4500	695.52	21697
19	4500	138.5	20131.6
20	5400	641.41	23534.8
21	4500	278	23524
22	5400	153.7	1734.23
23	5400	382.53	217252
24	4500	253.25	17392
25	4500	541.2	20517
26	4500	653.21	15621
27	4500	527.695	13964.435
28	4500	316.8	17691
Mean	4757.1	389.0	31393.8
SD	414.0	196.9	25765.8
P Value		0,000	




Fig. (1): The diagnosing, prescription dose, patient volume and PTV volume for the investigated cases

For evaluation of the target coverage, it was done in accordance to compare maximum and mean doses to PTV as well as numerous physical indices that were calculated such as ($[D_{98\% (cGy)}]$, $[D_{95\% (cGy)}]$, $[D_{5\% (cGy)}]$, $[V_{95\% (\%)}]$ and $[V_{107\% (\%)}]$. Where D_{min} is the minimum dose delivered by percentage value of the PTV. Within PTV, evaluation of the dose homogeneity was done by using Homogeneity Index (HI) as identified by:

HI= D5% /D95%

Where D95% and D5% indicated the dose levels on the curve Dose-Volume Histogram (DVH) which are corresponding to 95% and 5 % of the target volume, respectively. The HI values, which are near to unity, are indication for higher homogeneity.

For organ at risk, the dose-volume parameters were analyzed for each plan at 6 MV, 10MV and DE by comparing several physical indices. For right lung and left lung, irradiated volumes receiving more than 5, 10, 20, and 30 Gy ($V_{5 \text{ Gy}}$, $V_{10 \text{ Gy}}$, $V_{20 \text{ Gy}}$ and $V_{30 \text{ Gy}}$) also D_{mean} , $D_{1\%}$ and $D_{5\%}$ of the lung were calculated. In the remaining cases, the mean doses were calculated [9] for liver and kidney.

RESULTS

3.1. The Target Homogeneity and Conformity

Figure (2) shows the DVH's for 6-MV, 10-MV and DE treatment plans for the liver of some investigated cases. The results of 6 MV plans were shown in a form of large dashed lines (liver IMRT1) ,the results of 10 MV plans were shown as solid lines(liver IMRT 10mv. and the results of DE MV plans were shown as small dash lines within the majority of the cases, each energy plans has given a similar PTV coverage. Tables (2 and 3) show the target coverage parameters at 6, 10 MV and DE. Figures (3) shows the homogeneity index and the dose-volume parameters of PTV such as D 98 %, D95% and D5%. The quantitative analysis of the results revealed that there were no obvious variations in homogeneity index (HI) among 6 MV, 10 Photon beams (average 1.102 ± 0.011 , 1.113 ± 0.015 , p < 0.532). Most dose volume indices of PTV are slightly better for 6-MV treatment than 10-MV and it was statistically significant at D5% (p < 0.027). Such a small difference indicates that the lower entrance dose from the high-energy's beam is recovered by the high exit dose. The results showed no differences on the conformity of target between 6-MV treatment plans and the 10-MV plans.




Fig. (2) : the DVH's for of the 6MV, 10MV and DE energies for some treatment plans of the investigated cases

Table (2): Show the mean dose and maximum dose (D_{max}) to the PTVs for the photon beams 6 MV ,10 MV and duel energy plans

Patient		D mean (cGy)		D Max (cGy)			
	6	10	6,10	6	10	6,10	
1	4519.4	4599.2	4555.8	4758	4833.8	4865.2	
2	4621.7	45821.4	4593.8	4871	4918.2	4854.7	
3	5527.9	5537	5533.8	5957	5880	5881.4	
4	4567.5	4587.9	4610.5	5106.4	4992.8	5061.4	
5	4592.4	4623.7	4602.7	4862.2	4933.9	4827.6	
6	4596.8	4649.1	4646.2	4967.3	5012.3	5007.4	
7	5427	5597.9	5579.3	5708.1	5895.3	5853.7	
8	4607	4636.7	4540.8	4860	4840.8	4747.7	
9	5482.1	5489.3	5452.6	5724	5963.2	5982.3	
10	5452.3	5483.1	55142	5914.4	5895.1	5889.5	
11	4523.3	4543.1	4512.4	4878.4	4891.3	4925.2	
12	4668.2	4730.2	4550.2	5027.3	5187	4954.9	
13	4519.4	4599.2	4555.8	4758	4833.8	4865.2	
14	4621.7	45821.4	4593.8	4871	4918.2	4854.7	
15	5527.9	5537	5533.8	5957	5880	5881.4	
16	4567.5	4587.9	4610.5	5106.4	4992.8	5061.4	
17	4592.4	4623.7	4602.7	4862.2	4933.9	4827.6	
18	4596.8	4649.1	4646.2	4967.3	5012.3	5007.4	
19	5427	5597.9	5579.3	5708.1	5895.3	5853.7	
20	4607	4636.7	4540.8	4860	4840.8	4747.7	
21	5482.1	5489.3	5452.6	5724	5963.2	5982.3	
22	5452.3	5483.1	55142	5914.4	5895.1	5889.5	
23	4523.3	4543.1	4512.4	4878.4	4891.3	4925.2	
24	4668.2	4730.2	4550.2	5027.3	5187	4954.9	
25	4519.4	4599.2	4555.8	4758	4833.8	4865.2	
26	4621.7	45821.4	4593.8	4871	4918.2	4854.7	
27	5527.9	5537	5533.8	5957	5880	5881.4	
28	4567.5	4587.9	4610.5	5106.4	4992.8	5061.4	
Mean	4871.70	9326.53	8426.22	5212.88	5254.01	5227.31	
SD	427.66	12881.09	13200.86	454.28	464,84	478.62	
P Value		0.260106			0.949095		




Fig. (3): The mean dose and maximum dose

Table (3): Show the volume received 95% and 107% of dose (V95%, V107%) to the PTVs for the 6MV, 10MV and DE plans

Patient		V95% (%)			V107% (%)	
ratient	6	10	6,10	6	10	6,10
1	98.22	99.54	98.15	0.22	0.33	0.09
2	99.69	99.97	99.46	0	0	0
3	99.71	98.95	99.36	0.02	0.02	0.01
4	95.79	96.86	97.06	2.83	2.56	3.9
5	99.69	99.87	99.86	0	0.02	0
6	99.62	98.68	98.71	0.85	3.21	3.09
7	99.99	100	100	0	0.09	0.08
8	99.53	100	99.94	0	0.01	0
9	97.12	95.98	92.80	7.66	3.721	0.34
10	98.22	99.54	98.15	0.22	0.33	0.09
11	99.69	99.97	99.46	0	0	0
12	99.71	98.95	99.36	0.02	0.02	0.01 3.9
13	95.79	96.86	97.06	2.83	2.56	
14	99.69	99.87	99.86	0	0.02	0
15	99.62	98.68	98.71	0.85	3.21	3.09
16	99.99	100	100	0	0.09	0.08
17	99.53	100	99.94	0	0.01	0
18	97.12	95.98	92.80	7.66	3.721	0.34
19	98.22	99.54	98.15	0.22	0.33	0.09
20	99.69	99.97	99.46	0	0	0
21	99.71	98.95	99.36	0.02	0.02	0.01
22	95.79	96.86	97.06	2.83	2.56	3.9
23	99.69	99.87	99.86	0	0.02	0
24	99.62	98.68	98.71	0.85	3.21	3.09
25	99.99	100	100	0	0.09	0.08
26	99.53	100	99.94	0	0.01	0
27	97.12	95.98	92.80	7.66	3.721	0.34
28	98.22	99.54	98.15	0.22	0.33	0.09
Mean	98.80	98.90	98.36	1.25	1.08	0.90
SD	1.39	1.41	2.17	2.42	1.49	1.50
P Value		0.506382			0.666759	




Fig. (4): The volume received 107% to the PTVs for the 6MV, 10MV and DE plans




Fig. (5): The volume received 95% to the PTVs for the 6MV, 10MV and DE plans

3.2. Doses for different organs

Dose to Lung, Kidney and Liver

In both lungs, 10-MV plans gave better sparing of in various dose volume parameters however, there were no statistically significant difference in the results except in D5% of left lung (p < 0.01). In addition, DVHs for kidneys and liver exhibit the same behavior of the lung. 6 MV and 10 MV plans provided the mean doses of liver and kidneys below the tolerance limits.

Dose for Normal Tissue

The body volumes D2% and D5% doses received a slightly lower dose with 10-MV than 6-MV photon beams. For D5%, the change was statistically significant (p < 0.05426) (Table 5). For each patient, the receiving V_{2%}CGy and V_{5%}CGy were compared. The general tendency was that 10 MV treatment plans showed the lowest volume received in more than 2 and 5 Gy, and 6 MV beams treatment plans showed the highest volume.

OAR	DVH parameters	10 MV	6 MV	P value
	V5Gy (%)	62.46±31.04	62.95±30.81	0.189
	V10Gy (%)	62.46 ± 31.04 62.95 ± 30.81 0.18 48.3 ± 33.73 47.63 ± 34.42 0.22 26.18 ± 26.24 26.46 ± 26.55 $0.4'$ 18.17 ± 23.16 18.26 ± 20.28 $0.1'$ 37.82 ± 23.31 37.82 ± 21.84 0.88 35.71 ± 24.67 35.69 ± 25.39 0.64 16.98 ± 8.98 16.87 ± 9.61 0.22 80.31 ± 4.98 81 ± 5.12 0.33 56.98 ± 21.10 56.99 ± 20.21 0.4 30 ± 23.88 30.89 ± 24.11 0.33 18.89 ± 21.42 18.23 ± 21.51 $0.1'$ 43.3 ± 17.52 43.43 ± 17.51 0.52 40.1 ± 18.76 40.46 ± 18.75 0.00 8.4 ± 2.98 8.5 ± 2.84 0.00	0.22	
DT lung	V20Gy (%)	26.18±26.24	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	
RT lung	V30Gy (%)	18.17±23.16	18.26±20.28	0.17
	D1% (Gy)	37.82±23.31	37.82±21.84	0.86
	D5% (Gy)	35.71±24.67	35.69±25.39	0.64
	Mean	16.98±8.98	16.87±9.61	0.25
	$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	0.35		
	V10Gy (%)	10 Gy (%) 48.3 ± 33.73 47.63 ± 34.42 0.7 10 Gy (%) 26.18 ± 26.24 26.46 ± 26.55 0.7 12 GGy (%) 18.17 ± 23.16 18.26 ± 20.28 0.7 13 GGy (%) 18.17 ± 23.16 18.26 ± 20.28 0.7 01% (Gy) 37.82 ± 23.31 37.82 ± 21.84 0.7 05% (Gy) 35.71 ± 24.67 35.69 ± 25.39 0.7 Mean 16.98 ± 8.98 16.87 ± 9.61 0.7 10 Gy (%) 80.31 ± 4.98 81 ± 5.12 0.7 10 Gy (%) 56.98 ± 21.10 56.99 ± 20.21 0.7 12 GGy (%) 30 ± 23.88 30.89 ± 24.11 0.7 130 Gy (%) 18.89 ± 21.42 18.23 ± 21.51 0.7 01% (Gy) 43.3 ± 17.52 43.43 ± 17.51 0.7 05% (Gy) 40.1 ± 18.76 40.46 ± 18.75 0.7 Mean (Gy) 9.52 ± 4.5 9.62 ± 4.64 0.7 Mean (Gy) 8.4 ± 2.98 8.5 ± 2.84 0.07	0.41	
LT lung	V20Gy (%)		0.32	
	V30Gy (%)	18.89±21.42	$\begin{array}{c cccc} 26.46 \pm 26.55 \\ 18.26 \pm 20.28 \\ 37.82 \pm 21.84 \\ 35.69 \pm 25.39 \\ 16.87 \pm 9.61 \\ 81 \pm 5.12 \\ 56.99 \pm 20.21 \\ 30.89 \pm 24.11 \\ 18.23 \pm 21.51 \\ 43.43 \pm 17.51 \\ 40.46 \pm 18.75 \\ 9.62 \pm 4.64 \\ 8.5 \pm 2.84 \end{array}$	0.17
	D1% (Gy)	43.3±17.52	43.43±17.51	0.54
	D5% (Gy)	40.1±18.76	40.46±18.75	0.01
RT kidney	Mean (Gy)	9.52±4.5	9.62±4.64	0.04
LT kidney	Mean (Gy)	8.4 ± 2.98	8.5±2.84	0.001
Liver	Mean (Gy)	6.03±2.2	6.21±2.11	0.22

Table (4): the dose	-volume parameters for the differ	rent OAR according to the diffe	rent cases at all energies

Table (5): A comparison low dose distribution in healthy tissue

Patient	tient D2% (CGy)		·)]	D5%(CGy	r)		V2%CG	y	V5%CGy		
no	6	10	6+10	6	10	6+10	6	10	6+10	6	10	6+10
1	2924.6	2849.7	2948	1992.8	1927.6	1948.3	19.56	18.91	19.15	13.26	13.88	13.41
2	3121.8	3204.7	3154.1	1955.9	1923.4	1901.7	27.89	27.62	26.46	17.82	18.53	18.09
3	2202.7	2168.4	218.4	1635.6	1607.8	1603.7	25.75	25.72	25.39	18.17	18.66	18.39
4	3045.9	2917.6	2980.6	1347	1387.5	1393.1	23.85	2392	23.99	14.03	14.99	14.72
5	1758	1678.2	1731.9	1417.2	1188.4	1223.4	19.80	19.39	19.35	11.81	12.39	11.68
6	2776	3202.4	3229.1	2035.8	2268.9	23278	36.77	36.27	36.97	27.02	25.29	25.34
7	2546.7	2550.1	2480.8	1852.7	1773.1	1857.6	22.24	22.01	21.99	16.63	17.45	16.65
8	1786.3	1738.4	1802.9	858.3	1009.1	971.4	11.13	11.80	11.72	6.88	7.94	7.22
9	3137.5	3036.6	2930.4	2429.8	2417.2	2328.1	28.8	27.85	27.89	20.47	20.77	19.96
10	2924.6	2849.7	2948	1992.8	1927.6	1948.3	19.56	18.91	19.15	13.26	13.88	13.41
11	3121.8	3204.7	3154.1	1955.9	1923.4	1901.7	27.89	27.62	26.46	17.82	18.53	18.09
12	2202.7	2168.4	218.4	1635.6	1607.8	1603.7	25.75	25.72	25.39	18.17	18.66	18.39
13	3045.9	2917.6	2980.6	1347	1387.5	1393.1	23.85	2392	23.99	14.03	14.99	14.72
14	1758	1678.2	1731.9	1417.2	1188.4	1223.4	19.80	19.39	19.35	11.81	12.39	11.68
15	2776	3202.4	3229.1	2035.8	2268.9	23278	36.77	36.27	36.97	27.02	25.29	25.34
16	2546.7	2550.1	2480.8	1852.7	1773.1	1857.6	22.24	22.01	21.99	16.63	17.45	16.65
17	1786.3	1738.4	1802.9	858.3	1009.1	971.4	11.13	11.80	11.72	6.88	7.94	7.22
18	3137.5	3036.6	2930.4	2429.8	2417.2	2328.1	28.8	27.85	27.89	20.47	20.77	19.96
19	2924.6	2849.7	2948	1992.8	1927.6	1948.3	19.56	18.91	19.15	13.26	13.88	13.41
20	3121.8	3204.7	3154.1	1955.9	1923.4	1901.7	27.89	27.62	26.46	17.82	18.53	18.09
21	2202.7	2168.4	218.4	1635.6	1607.8	1603.7	25.75	25.72	25.39	18.17	18.66	18.39
22	3045.9	2917.6	2980.6	1347	1387.5	1393.1	23.85	2392	23.99	14.03	14.99	14.72
23	2924.6	2849.7	2948	1992.8	1927.6	1948.3	19.56	18.91	19.15	13.26	13.88	13.41
24	3121.8	3204.7	3154.1	1955.9	1923.4	1901.7	27.89	27.62	26.46	17.82	18.53	18.09
25	2202.7	2168.4	218.4	1635.6	1607.8	1603.7	25.75	25.72	25.39	18.17	18.66	18.39
26	3045.9	2917.6	2980.6	1347	1387.5	1393.1	23.85	2392	23.99	14.03	14.99	14.72
27	1758	1678.2	1731.9	1417.2	1188.4	1223.4	19.80	19.39	19.35	11.81	12.39	11.68
28	2776	3202.4	3229.1	2035.8	2268.9	23278	36.77	36.27	36.97	27.02	25.29	25.34
Mean	2633.0	2637.6	2375.6	1727.4	1719.9	3971.6	24.4	362.4	24.0	16.3	16.8	16.3
SD	510.4	555.4	1028.0	394.7	411.4	6819.8	6.3	843.8	6.2	5.1	4.5	4.6
P Value		0.317987			0.05426			0.014048			0.923365	5

DISCUSSION

IMRT is considered one of the major critical advancements in radiotherapy in current years. It can provide the capability of improving clinical outcomes and decrease morbidity. IMRT, indeed, is still developing as a therapeutic modality, but once launched, it is likely to lower the times of planning and treatment.

In the current study, the effect of 6MV, 10MV, and DE beams' energy on liver cancer with a higher target dose compactness were evaluated in the IMRT delivery technique.

Comparing all the above parameters, it was shown that there was a slight variation between 6MV, 10MV, and DE. Both lungs' 10MV plans were continually superior on 6MV plans, but both were clinically equivalent because the lung is a comparatively a large organ. Therefore, while it exhibits a higher partial volume effect, a small increase in dose is unlikely to elevate its complication possibility which is considerably similar and in agreement with previously published data[10].

The role of using different energies in the current study is reflected due to the power of penetration, the irradiated volume of integral dose and the low dose increase in 6MV plans. Acute or sub-acute clinical morbidity might not be caused by that low-dose volume; however, it might possibly be carcinogenic [11]. Statistically, the results showed significant variations between 6MV and 10MV for the parameters. In a study on the investigation of the feasibility of 6MV intensitymodulated photons usage for the treatment of very large prostate cancer patients, by Sun and Ma, it was shown that using the 6MV is an efficient choice for treating even very large prostate cancer patients [12].

In addition, photon beams of lower energy (6 MV) were more preferable than higher energies (15 - 18MV) in treating tumors that adjoin lung tissues [13]. Another study by Gopi solaiappan et al., investigating the effect of beam energy on the IMRT plans quality, with detailed analysis to all the DVH parameters, using 6MV photons for IMRT of prostate cancer was recommended [14]. Consequently, nearly the total of previous researches revealed that the use of low-energy photon beams in IMRT was more favored than the higher energies.

However, the situation in 10MV usage was different as 10MV photon beams areon the threshold energies border for the stimulation of lethal secondary cancers.

In a study by Sung W et al., in which a comparison on the effect of three-photon energies (6MV, 10MV, and 15MV) was conducted on IMRT plans for treatment of twenty patients with prostate cancer, it was found that 10MV plans revealed better OARs sparing and fewer integral doses than 6MV. In concord with that work, the present study suggests that using 10 MV photon beams was diametrical compared with 6MV photon beams in terms of homogeneity, target volume coverage, conformity, and OARs sparing. It was found that the normal tissues surrounding the target volume got higher doses for the 6MV than 10MV beams; however, it must be taken into account that there are no secondary neutrons associated with 6MV, and radiation seepage was somewhat low. In addition, 6MV photons had significant less room shielding requirements than those required for 10MV photons [15]. The uncertainty within the dose given to a patient must be between 3-5% [16]

CONCLUSION

It can be concluded that the use of high-energy 10-MV and DE photon in the treatment plan gives the same tumor control achieved by a 6-MV photon with some complications. Using this plan results in complications of an acceptable rate and saves the normal tissue. It is recommended that treatment options at 10 MV and DE should be considered a risk-versus-benefit strategy, as clinical significance remains to be determined according to the individual cases. the present study suggests the dosimetric benefits of high energies as well as low energy for liver treatment. Moreover, results of the current study could be applied to choose the best plan for HCC to compare OAR doses and select the best for patient treatment with target coverage.

REFERENCES

- S.Hassn, Nashaat A. Deiab, and Arafa H. Aly, " Dosimetric Study of photon Beam characteristics with 2D Array and water phantom Measurement" Int. J. Radiat. Res., Vol. 18(1), 167,2020.
- [2] Nakamura, Katsumasa, et al. Recent advances in radiation oncology: intensity-modulated radiotherapy, a clinical perspective. International journal of clinical oncology, 2014, 19.4: 564-569.
- [3] KIM, Jieun; JUNG, Youngmi. Radiation-induced liver disease: current understanding and future perspectives. Experimental & molecular medicine, 2017, 49.7: e359-e359.
- [4] Scorsetti, M., Comito, T., Cozzi, L., Clerici, E., Tozzi, A., Franzese, C., & Iftode, C. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on

Arab J. Nucl. Sci. Appl., Vol. 54, 4, (2021)

stereotactic body radiation therapy (SBRT). Journal of cancer research and clinical oncology, 2015, 141.7: 1301-1309.

- [5] Bae, Sun Hyun; JANG, Won IL; PARK, Hee Chul. Intensity-modulated radiotherapy for hepatocellular carcinoma: dosimetric and clinical results. Oncotarget, 2017, 8.35: 59965.
- [6] Choi, Seo Hee; SEONG, Jinsil. Strategic application of radiotherapy for hepatocellular carcinoma. Clinical and molecular hepatology, 2018, 24.2: 114.
- [7] Zhang, Haige, et al. Image-guided intensitymodulated radiotherapy improves short-term survival for abdominal lymph node metastases from hepatocellular carcinoma. Annals of Palliative Medicine, 2019, 8.5: 717-727.
- [8] Kim, J. W., Han, K. H., & Seong, J. Phase I/II trial of helical IMRT-based stereotactic body radiotherapy for hepatocellular carcinoma. Digestive and Liver Disease, 2019, 51.3: 445-451.
- [9] Benedict, S. Yenice, KM. Followill, D. et al. Stereotactic body radiation therapy: The report of AAPM Task Group 101. Med.Phys. 37(8):4078-4101;2010.
- [10] HAURI, Pascal; SCHNEIDER, Uwe. Whole-body dose equivalent including neutrons is similar for 6 MV and 15 MV IMRT, VMAT, and 3D conformal radiotherapy. Journal of applied clinical medical physics, 2019, 20.3: 56-70.
- [11] TAMILARASU, Suresh, et al. Comparative Evaluation of a 6MV Flattened Beam and

a Flattening Filter Free Beam for Carcinoma of Cervix–IMRT Planning Study. Asian Pacific journal of cancer prevention: APJCP, 2018, 19.3: 639.

- [12] AL-SHAREEF, Jamal, et al. Comparison of intensity modulated and 3-dimensional conformal radiotherapy for prostate cancer using 6-MV and 15-MV photon energies. Arab Journal of Nuclear Sciences and Applications, 2020, 53.2: 189-200.
- [13] Eldesoky, Ismail, Ehab M. Attalla, and Wael M. Elshemey. "The Dosimetric Effects of Different Beam Energy on Physical Dose Distributions in IMRT Based on Analysis of Physical Indices." Journal of Cancer Therapy 4.11, 2013, 33.
- [14] G. Solaiappan, G. Singaravelu, A. Prakasarao, B. Rabbani and S. S. Supe, "Influence of Photon Beam Energy on IMRT Plan Quality for Radiotherapy of Prostate Cancer," Reports of Practical Oncology and Radiotherapy, Vol. 14, No. 1, 2009, pp. 18-31.
- [15] W. Sung, J. M. Park, C. H. Choi, S. W. Ha and S. J. Ye, "The Effect of Photon Energy on Intensity-Modulated Ra- diation Therapy (IMRT) Plans for Prostate Cancer," Jour- nal of Radiation Oncology, Vol. 30, No. 1, 2012, pp. 27-35.
- [16] S. Hassn, Nashaat A. Deiab, and Arafa H. Aly " Comparative Study and Dose Evaluation of Photon Beam for water phantom, 2D-array and Treatment Planning System in Small Field sizes" Arab journal of nuclear sciences and applications, 2020,53,1,119-124.